11:35 AM EDT, 06/11/2025 (MT Newswires) -- Cogent Biosciences ( COGT ) said Wednesday it has obtained a debt facility of up to $400 million from credit funds managed by SLR Capital Partners.

A first tranche of $50 million was drawn at closing, Cogent said, adding that $100 million is available this year subject to successful top-line data from trials of bezuclastinib.

An additional $50 million will be available upon Cogent reaching early commercial success following the launch of bezuclastinib, the company said, adding the remaining $200 million will be available subject to Cogent and SLR's mutual agreement.

Cogent shares were down 1.1% in recent trading.

Price: 7.34, Change: -0.08, Percent Change: -1.08